Status:
TERMINATED
Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Diabetic Patient (Type 1,2, MODY, Secondary) or With Corticosteroid-induced Diabetes Following Initiation of Corticosteroid Treatment
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Diabetes is a major factor of morbi-mortality in Covid-19 infection. Currently, steroid therapy is required in patients under oxygen therapy. This treatment is associated with hyper glycaemia in patie...
Detailed Description
The study will take place in the infectious diseases department of the University Hospitals of Strasbourg. All diabetic patients or patients with corticosteroid-induced diabetes hospitalized for Covid...
Eligibility Criteria
Inclusion
- Patient adult hospitalized for Covid-19 infection in the Infectious Diseases Department of the University Hospital of Strasbourg (HUS)
- Patient requiring steroid treatment
- Diabetic patient (type 1,2, MODY, secondary) or with corticosteroid-induced diabetes following initiation of corticosteroid treatment
Exclusion
- Contraindication to the use of the Free-Style Medical Device
Key Trial Info
Start Date :
January 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 18 2022
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04726163
Start Date
January 29 2021
End Date
February 18 2022
Last Update
April 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopitaux Universitaires de Strasbourg
Strasbourg, France, 67091